<DOC>
	<DOCNO>NCT03036228</DOCNO>
	<brief_summary>The primary objective study determine safety tolerability Karonudib treatment cancer . Secondary objective determine recommend RP2D schedule development Karonudib , determine pharmacokinetics Karonudib , look evidence treatment efficacy . Overall survival also record .</brief_summary>
	<brief_title>MTH1 , A Phase I , Study Tumors Inhibition , First Human , First Class</brief_title>
	<detailed_description />
	<criteria>1 . Written informed consent . 2 . Age least 18 year ( upper age limit patient must judge `` biologic '' age 75 year less ) . 3 . Histological cytological confirmation cancer ( imaging/AFP sufficient patient HCC accord international standard ) . 4 . The patient receive standard care treatment progressive disease experimental therapy treatment option . 5 . Life expectancy least 12 week ( per investigator clinical assessment ) . 6 . ECOG PFS 0 1 . 7 . Patients must measurable disease base RECIST 1.1 criterion . 8 . Adequate bone marrow , hepatic renal function define : 1 . Haemoglobin ≥ 100 g/L ( blood transfusion le 21 day prior screen ) . 2 . Absolute neutrophil count ≥ 1.5 x 109/L , platelet ≥100 x 109/L . 3 . Total bilirubin &lt; 1.5 x ULN ( apply patient Gilberts Syndrome ) . 4 . AST ALT ≤ 1.5 x ULN ( ≤ 3 x ULN presence liver metastasis ) . 5 . Serum creatinine ≤ ULN ( serum creatinine 1 1.5 x ULN , patient may eligible provide calculated GFR least 50 ml/min use CockcroftGault method ) . 6 . Albumin great equal 24 g/L . 9 . Subject must able take oral medication . 10 . Negative pregnancy test accord CTFG guidance 2014 female childproducing potential . 1 . Age le 18 year . 2 . Less 4 week since stop previous systemic cancer treatment . 3 . Less 3 week since stop palliative radiotherapy . 4 . Less 3 week minor surgery . 5 . Less 6 month since clinically significant cardiovascular event myocardial infarction , unstable angina , angioplasty , bypass surgery , stroke TIA . 6 . Congestive heart failure NYHA class ≥ II . 7 . History arrhythmias arrhythmias discover screening period ( apart atrial fibrillation without ventricular tachycardia premature extra beat . 8 . Patients require antiarrhythmic drug . 9 . QTc interval &gt; 450 ms baseline . 10 . Use fentanyl ( must stop least 1 week prior initiation Karonudib ) . 11 . Use antioxidant vitamin acetylcysteine ( must stop within 48 hour start treatment Karonudib ) . 12 . Use antidepressant medication substrate CYP2D6 ( must stop least 3 week prior start treatment Karonudib ) . 13 . Any severe acute chronic medical condition place patient increase risk interferes interpretation study result . 14 . Leptomeningeal metastasis ( patient previously treat brain metastasis eligible provide evidence disease progression minimum 8 week prior inclusion case CNS MR require within screening period ) . 15 . Known acute chronic infection hepatitis B C. 16 . Known HIV infection . 17 . Pregnant breastfeed woman . 18 . Patients reproductive potential implementing accept effective mean contraception . 19 . Participation clinical trial within previous 4 week . 20 . Unable comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Solid tumour</keyword>
</DOC>